Cargando…
Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies
IMMH-010 is a prodrug of YPD-29B, which is a novel PD-L1 inhibitor. A specific and sensitive LC-MS/MS method with polarity switching was developed and validated for the simultaneous determination of IMMH-010 and YPD-29B in rat plasma, liver, brain, urine and fecal samples. Method validation was inve...
Autores principales: | Jiang, Jianwei, Zou, Xiaowen, Liu, Yuke, Liu, Xiao, Dong, Kai, Yao, Xiaoqing, Feng, Zhiqiang, Chen, Xiaoguang, Sheng, Li, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256334/ https://www.ncbi.nlm.nih.gov/pubmed/34234673 http://dx.doi.org/10.3389/fphar.2021.677120 |
Ejemplares similares
-
Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug
por: Wang, Yuchen, et al.
Publicado: (2021) -
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
por: Lai, Fangfang, et al.
Publicado: (2022) -
Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
por: Lai, Fangfang, et al.
Publicado: (2023) -
Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry
por: Śniegocki, Tomasz, et al.
Publicado: (2021) -
A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models
por: Jin, Jing, et al.
Publicado: (2020)